First-pass extracted concept

oncolytic virus therapy

Candidate: concept label1 source documents7 linked claims
Live refresh every 5sNext refresh in 5s

Aliases

OVs therapy, OV therapy

Extracted Explainers

What the tool is doing

Oncolytic virus therapy is presented as a cancer immunotherapy modality with multifaceted mechanisms of tumor elimination.

Source 1DOIPubMed

What problem it solves

It aims to eliminate tumors and stimulate antitumor immunity.

Source 1DOIPubMed

What it does not solve

As described in the abstract, OV monotherapy remains limited by physiological barriers, delivery constraints, and insufficient immune activation.

Source 1DOIPubMed

Alternatives

The abstract contrasts OV monotherapy with combination use alongside phototherapy.

Source 1DOIPubMed

Evidence Snippets

Oncolytic virus (OVs) therapy has emerged as a promising modality in cancer immunotherapy.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1application scopesupports2025Source 1DOIPubMed

The OV-phototherapy combination literature discussed in the source includes optical imaging-guided diagnosis and optogenetically controlled delivery applications.

Quoted textsource-backed
It also explores their applications in optical imaging-guided diagnosis and optogenetically controlled delivery.
Claim 2combination effectsupports2025Source 1DOIPubMed

Phototherapy used in conjunction with oncolytic viruses can enhance viral delivery, amplify tumor destruction, and boost antitumor immune responses.

Quoted textsource-backed
Phototherapy, an innovative and rapidly advancing cancer treatment technology, can mitigate these limitations when used in conjunction with OVs, enhancing viral delivery, amplifying tumor destruction, and boosting antitumor immune responses.
Claim 3development stagesupports2025Source 1DOIPubMed

Combined OV-phototherapy strategies are promising in preclinical models but remain largely in early-stage research.

Quoted textsource-backed
While promising in preclinical models, these combined strategies are still largely in early-stage research.
Claim 4limitationsupports2025Source 1DOIPubMed

The efficacy of oncolytic virus therapy as a monotherapy is constrained by physiological barriers, limited delivery routes, and suboptimal immune activation.

Quoted textsource-backed
However, its efficacy as a monotherapy remains constrained by physiological barriers, limited delivery routes, and suboptimal immune activation.
Claim 5scope statementsupports2025Source 1DOIPubMed

The review analyzes synergistic integration of oncolytic viruses with photodynamic therapy and photothermal therapy.

Quoted textsource-backed
This review provides the first comprehensive analysis of synergistic integration of OVs with both photodynamic therapy (PDT) and photothermal therapy (PTT).
Claim 6therapeutic rationalesupports2025Source 1DOIPubMed

Oncolytic virus therapy is a promising modality in cancer immunotherapy.

Quoted textsource-backed
Oncolytic virus (OVs) therapy has emerged as a promising modality in cancer immunotherapy
Claim 7translation limitationsupports2025Source 1DOIPubMed

Clinical translation of combined OV-phototherapy strategies is limited by light penetration, delivery efficiency, and safety concerns.

Quoted textsource-backed
Challenges such as limited light penetration, delivery efficiency, and safety concerns remain to be addressed for clinical translation.